Preclinical
Although progress has been made in treating the disease, it’s still often fatal, and is made up of multiple diseases.
Orion Biotechnology Canada Ltd., announced new preclinical data evaluating the efficacy of OB-002 in colorectal cancer.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial.
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
Amarantus Bioscience Holdings, Inc. announced that positive results from in vitro and animal studies on MANF in the treatment of Wolfram Syndrome were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
Calithera Biosciences, Inc. announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma.
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
MyoKardia, Inc., presented data at the European Society of Cardiology Heart Failure Congress from its Phase 1a single-ascending dose study of MYK-491 in healthy volunteers.
Medigene AG announces that two scientific posters with preclinical data on an HA-1-specific T-cell receptor and a NY-ESO-1/LAGE-1-specific T-cell receptor were shown on 21 May 2019 during the CIMT Annual Meeting in Mainz.
PRESS RELEASES